CA3165813A1 - Modulators of the integrated stress response pathway - Google Patents
Modulators of the integrated stress response pathway Download PDFInfo
- Publication number
- CA3165813A1 CA3165813A1 CA3165813A CA3165813A CA3165813A1 CA 3165813 A1 CA3165813 A1 CA 3165813A1 CA 3165813 A CA3165813 A CA 3165813A CA 3165813 A CA3165813 A CA 3165813A CA 3165813 A1 CA3165813 A1 CA 3165813A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- optionally substituted
- compound
- pharmaceutically acceptable
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20162329.5 | 2020-03-11 | ||
| EP20162329 | 2020-03-11 | ||
| PCT/EP2021/056023 WO2021180774A1 (en) | 2020-03-11 | 2021-03-10 | Modulators of the integrated stress response pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3165813A1 true CA3165813A1 (en) | 2021-09-16 |
Family
ID=69804610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3165813A Pending CA3165813A1 (en) | 2020-03-11 | 2021-03-10 | Modulators of the integrated stress response pathway |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12441720B2 (enExample) |
| EP (1) | EP4117780B1 (enExample) |
| JP (1) | JP2023517944A (enExample) |
| KR (1) | KR20220151635A (enExample) |
| CN (1) | CN115190813B (enExample) |
| AU (1) | AU2021236284B2 (enExample) |
| BR (1) | BR112022014706A2 (enExample) |
| CA (1) | CA3165813A1 (enExample) |
| IL (1) | IL296220A (enExample) |
| MX (1) | MX2022011143A (enExample) |
| WO (1) | WO2021180774A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3137212A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| AU2021363616B2 (en) * | 2020-10-22 | 2026-03-26 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| KR20230110509A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| MX2023004626A (es) | 2020-10-22 | 2023-05-23 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
| DE102023120315A1 (de) * | 2023-07-31 | 2025-02-06 | Rheinisch-Westfälische Technische Hochschule Aachen, abgekürzt RWTH Aachen, Körperschaft des öffentlichen Rechts | Verfahren zur Herstellung von Pyrrolidon-substituierten Polyolen |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0988301B1 (en) | 1997-06-12 | 2006-08-09 | Aventis Pharma Limited | Imidazolyl-cyclic acetals |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| KR20190015492A (ko) | 2016-06-08 | 2019-02-13 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CA3068753A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CA3068395A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| HUE062446T2 (hu) * | 2017-09-01 | 2023-11-28 | Denali Therapeutics Inc | Vegyületek, készítmények és eljárások |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018358157B2 (en) | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| CA3080948A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| SG11202004009TA (en) * | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090078A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704089B1 (en) | 2017-11-02 | 2023-07-19 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| AU2018383675A1 (en) | 2017-12-13 | 2020-07-09 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| EP3768660A1 (en) | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| MX2020013269A (es) | 2018-06-05 | 2021-02-18 | Praxis Biotech LLC | Inhibidores de la vía de respuesta al estrés integrada. |
| EP3820843A1 (en) | 2018-07-09 | 2021-05-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| EP3923935A4 (en) | 2019-02-13 | 2022-10-26 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| CN113840597A (zh) | 2019-02-25 | 2021-12-24 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路抑制剂 |
| WO2020181247A1 (en) | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3137212A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| IL287379B2 (en) | 2019-04-23 | 2025-11-01 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| PE20220572A1 (es) | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| EP3962899A1 (en) | 2019-04-30 | 2022-03-09 | Calico Life Sciences LLC | Substituted cyclolakyls as modulators of the integrated stress pathway |
| KR20220024486A (ko) | 2019-06-12 | 2022-03-03 | 프락시스 바이오테크 엘엘씨 | 통합 스트레스 반응 경로의 억제제 |
| CN114466654A (zh) | 2019-06-12 | 2022-05-10 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路调节剂 |
| EP4096665A1 (en) | 2020-01-28 | 2022-12-07 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| KR20230110509A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| MX2023004626A (es) | 2020-10-22 | 2023-05-23 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| AU2021363616B2 (en) | 2020-10-22 | 2026-03-26 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
-
2021
- 2021-03-10 CA CA3165813A patent/CA3165813A1/en active Pending
- 2021-03-10 CN CN202180020265.6A patent/CN115190813B/zh active Active
- 2021-03-10 KR KR1020227033901A patent/KR20220151635A/ko active Pending
- 2021-03-10 WO PCT/EP2021/056023 patent/WO2021180774A1/en not_active Ceased
- 2021-03-10 BR BR112022014706A patent/BR112022014706A2/pt unknown
- 2021-03-10 EP EP21710001.5A patent/EP4117780B1/en active Active
- 2021-03-10 JP JP2022554500A patent/JP2023517944A/ja active Pending
- 2021-03-10 MX MX2022011143A patent/MX2022011143A/es unknown
- 2021-03-10 US US17/906,014 patent/US12441720B2/en active Active
- 2021-03-10 IL IL296220A patent/IL296220A/en unknown
- 2021-03-10 AU AU2021236284A patent/AU2021236284B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230129907A1 (en) | 2023-04-27 |
| EP4117780A1 (en) | 2023-01-18 |
| CN115190813A (zh) | 2022-10-14 |
| BR112022014706A2 (pt) | 2022-10-11 |
| WO2021180774A1 (en) | 2021-09-16 |
| AU2021236284B2 (en) | 2026-03-26 |
| IL296220A (en) | 2022-11-01 |
| MX2022011143A (es) | 2022-10-13 |
| JP2023517944A (ja) | 2023-04-27 |
| AU2021236284A1 (en) | 2022-08-18 |
| US12441720B2 (en) | 2025-10-14 |
| KR20220151635A (ko) | 2022-11-15 |
| CN115190813B (zh) | 2024-10-15 |
| EP4117780B1 (en) | 2026-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4117780B1 (en) | Modulators of the integrated stress response pathway | |
| US12258338B2 (en) | Modulators of the integrated stress response pathway | |
| AU2020262153B2 (en) | Modulators of the integrated stress response pathway | |
| CA3162526A1 (en) | Modulators of the integrated stress response pathway | |
| AU2021363616B2 (en) | Modulators of the integrated stress response pathway | |
| WO2022084446A1 (en) | Modulators of the integrated stress response pathway | |
| EP4232154B1 (en) | Modulators of the integrated stress response pathway | |
| HK40116770A (en) | Modulators of the integrated stress response pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250130 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250130 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250130 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250219 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250304 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250508 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260211 |